Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Matthew S. Squires, PhD, Jayne E. Curry, Mark A. Dawson, Mike A. Scott, Kelly Barber, Matthias Reule, Tomoko Smyth, Nicola Wallis, Murray Yule, Neil T. Thompson, John F. Lyons, Anthony R. Green

Blood (2007) 110 (11): 3537.

https://doi.org/10.1182/blood.V110.11.3537.3537

Published: 2007

Journal Articles

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia

Linda M. Scott, Mike A. Scott, Peter J. Campbell, Anthony R. Green

Blood (2006) 108 (7): 2435–2437.

https://doi.org/10.1182/blood-2006-04-018259

Published: 2006

Includes: Supplemental data

Journal Articles

Conservation of unique cell-surface CD antigen mosaics in HIV-1–infected individuals

Adrian Woolfson, Justin Stebbing, Brian D. M. Tom, Kerryn J. Stoner, Walter R. Gilks, David P. Kreil, Stephen P. Mulligan, Larissa Belov, Jeremy S. Chrisp, Will Errington, Adrian Wildfire, Wendy N. Erber, Mark Bower, Brian Gazzard, Richard I. Christopherson, Mike A. Scott

Blood (2005) 106 (3): 1003–1007.

https://doi.org/10.1182/blood-2004-12-4642

Published: 2005

Journal Articles

The Application of Growth Factor Stimulants to Improve Ctogenetic Analysis of Patients with Myeloproliferative and Myelodysplastic Syndromes.

Beverley R. Vaughan, 2(1)Hons, Mike A. Scott, PhD, Elizabeth P. Nachva, MD PhD

Blood (2004) 104 (11): 2003.

https://doi.org/10.1182/blood.V104.11.2003.2003

Published: 2004

Journal Articles

Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability

Brian J. P. Huntly, Anthony J. Bench, Eric Delabesse, Alistair G. Reid, Juan Li, Mike A. Scott, Lynda Campbell, Jennie Byrne, Eleanor Pinto, Andre Brizard, Deitger Niedermeiser, Elizabeth P. Nacheva, Francois Guilhot, Michael Deininger, Anthony R. Green

Blood (2002) 99 (12): 4547–4553.

https://doi.org/10.1182/blood.V99.12.4547

Published: 2002

NARROW

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia

Conservation of unique cell-surface CD antigen mosaics in HIV-1–infected individuals

The Application of Growth Factor Stimulants to Improve Ctogenetic Analysis of Patients with Myeloproliferative and Myelodysplastic Syndromes.

Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability

Email alerts

ASH Publications

American Society of Hematology

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia

Conservation of unique cell-surface CD antigen mosaics in HIV-1–infected individuals

The Application of Growth Factor Stimulants to Improve Ctogenetic Analysis of Patients with Myeloproliferative and Myelodysplastic Syndromes.

Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only